LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Elanco Animal Health Inc

Cerrado

SectorSanidad

12.93 0.47

Resumen

Variación precio

24h

Actual

Mínimo

12.68

Máximo

12.99

Métricas clave

By Trading Economics

Ingresos

75M

67M

Ventas

173M

1.2B

P/B

Media del Sector

17.093

56.602

BPA

0.37

Margen de beneficios

5.616

Empleados

9,000

EBITDA

86M

261M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+13.06% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.6B

6.4B

Apertura anterior

12.46

Cierre anterior

12.93

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

173 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Elanco Animal Health Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2025, 11:29 UTC

Adquisiciones, fusiones, absorciones

Elanco Sells Non-Core Asset to Blackstone for $295 Million

27 jun 2024, 14:34 UTC

Principales Movimientos del Mercado

Elanco Shares Retreat Over Zenrelia Warning Label Concerns

5 may 2025, 11:14 UTC

Adquisiciones, fusiones, absorciones

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5 may 2025, 10:50 UTC

Adquisiciones, fusiones, absorciones

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5 may 2025, 10:49 UTC

Adquisiciones, fusiones, absorciones

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

9 jul 2024, 12:30 UTC

Adquisiciones, fusiones, absorciones

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9 jul 2024, 12:29 UTC

Adquisiciones, fusiones, absorciones

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

9 jul 2024, 12:28 UTC

Adquisiciones, fusiones, absorciones

Elanco Animal Health: $1.05B-$1.1B Net Proceeds Available for Debt Paydown in 3Q >ELAN

9 jul 2024, 12:28 UTC

Adquisiciones, fusiones, absorciones

Elanco Completes Sale of Aqua Business to Merck >ELAN MRK

Comparación entre iguales

Cambio de precio

Elanco Animal Health Inc previsión

Precio Objetivo

By TipRanks

13.06% repunte

Estimación a 12 Meses

Media 14.63 USD  13.06%

Máximo 20 USD

Mínimo 10 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Elanco Animal Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.77 / N/ASoporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

173 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.